Innovative Approaches to Target Identification and Assay Development for Fungal Diagnosis (R21/R33)

archived

-Purpose. This Funding Opportunity Announcement (FOA), titled Innovative Approaches to Target Identification and Assay Development for Fungal Diagnosis, and issued by the NIAID, National Institutes of Health, solicits applications to foster collaborative efforts between the mycology research community and the innovative technology sector to develop novel clinical diagnostic targets and subsequent assays for invasive aspergillosis (IA) and other invasive fungal diseases common to immunocompromised or immunosuppressed patients. Ultimately, research sponsored in response to this FOA should lead to the development of a novel diagnostic test(s) for detection of invasive fungal disease(s) that must include invasive aspergillosis.-Mechanism of Support. This FOA will utilize the NIH R21/R33 Phased Innovation Award to support innovative exploratory and developmental research. Under the R21 phase, research is initiated and carried out through a milestone-driven process to establish the feasibility of new diagnostics, diagnostic strategies and support technologies. The R33 phase then provides the support required to translate the innovation discoveries into the preclinical/clinical development pipeline.-Funds Available and Anticipated Number of Awards. The total amount of funding that the NIAID intends to commit to this announcement is $1.5 million in FY 2010 to fund five to seven grants. Funding will be based on scientific and technical merit, program priorities, and availability of funds. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.

High